Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | ONCOS-102 |
| Trade Name | |
| Synonyms | ONCOS102|CGTG-102 |
| Drug Descriptions |
ONCOS-102 is an adenovirus engineered to express granulocyte macrophage colony stimulating factor (GMCSF), which induces anti-tumor immune response (PMID: 26981247, PMID: 31944306). |
| DrugClasses | |
| CAS Registry Number | 1802359-98-3 |
| NCIT ID | C98287 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Cyclophosphamide + ONCOS-102 + Pembrolizumab | Cyclophosphamide ONCOS-102 Pembrolizumab | 0 | 1 |
| Durvalumab + ONCOS-102 | Durvalumab ONCOS-102 | 0 | 1 |
| ONCOS-102 | ONCOS-102 | 0 | 0 |
| ONCOS-102 + Pembrolizumab | ONCOS-102 Pembrolizumab | 0 | 0 |